Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Lambert, JD; Meyers, RO; Timmermann, BN; Dorr, RT
   Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse
   JOURNAL OF CHROMATOGRAPHY B
   
   J.D. Lambert et al., "Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse", J CHROMAT B, 754(1), 2001, pp. 85-90
2. Waltmire, CN; Alberts, DS; Dorr, RT
   Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer
   ANTI-CANCER DRUGS
   
   C.N. Waltmire et al., "Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer", ANTI-CANC D, 12(7), 2001, pp. 595-602
3. Dorr, RT; Liddil, JD; Sami, SM; Remers, W; Hersh, EM; Alberts, DS
   Preclinical antitumor activity of the azonafide series of anthracene-basedDNA intercalators
   ANTI-CANCER DRUGS
   
   R.T. Dorr et al., "Preclinical antitumor activity of the azonafide series of anthracene-basedDNA intercalators", ANTI-CANC D, 12(3), 2001, pp. 213-220
4. Taylor, CW; Dorr, RT; Fanta, P; Hersh, EM; Salmon, SE
   A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugatedL-asparaginase in patients with advanced solid tumors
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   C.W. Taylor et al., "A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugatedL-asparaginase in patients with advanced solid tumors", CANC CHEMOT, 47(1), 2001, pp. 83-88
5. Baker, AF; Dorr, RT
   Drug interactions with the taxanes: clinical implications
   CANCER TREATMENT REVIEWS
   
   A.F. Baker e R.T. Dorr, "Drug interactions with the taxanes: clinical implications", CANC TR REV, 27(4), 2001, pp. 221-233
6. Lambert, JD; Meyers, RO; Timmermann, BN; Dorr, RT
   tetra-O-Methylnordihydroguaiaretic acid inhibits melanoma in vivo
   CANCER LETTERS
   
   J.D. Lambert et al., "tetra-O-Methylnordihydroguaiaretic acid inhibits melanoma in vivo", CANCER LETT, 171(1), 2001, pp. 47-56
7. Skibo, EB; Xing, CG; Dorr, RT
   Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: Structure-activity relationships for cytotoxicity and antitumor activity
   JOURNAL OF MEDICINAL CHEMISTRY
   
   E.B. Skibo et al., "Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: Structure-activity relationships for cytotoxicity and antitumor activity", J MED CHEM, 44(22), 2001, pp. 3545-3562
8. Dvorakova, K; Waltmire, CN; Payne, CM; Tome, ME; Briehl, MM; Dorr, RT
   Induction of mitochondrial changes in myeloma cells by imexon
   BLOOD
   
   K. Dvorakova et al., "Induction of mitochondrial changes in myeloma cells by imexon", BLOOD, 97(11), 2001, pp. 3544-3551
9. Zhou, Q; Duan, WH; Simmons, D; Shayo, Y; Raymond, MA; Dorr, RT; Hurley, LH
   Design and synthesis of a novel DNA-DNA interstrand adenine-guanine cross-linking agent
   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
   
   Q. Zhou et al., "Design and synthesis of a novel DNA-DNA interstrand adenine-guanine cross-linking agent", J AM CHEM S, 123(20), 2001, pp. 4865-4866
10. Alberts, DS; Dorr, RT; Einspahr, JG; Aickin, M; Saboda, K; Xu, MJ; Peng, YM; Goldman, R; Foote, JA; Warneke, JA; Salasche, S; Roe, DJ; Bowden, GT
    Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
    
    D.S. Alberts et al., "Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine", CANC EPID B, 9(12), 2000, pp. 1281-1286
11. Stratton, SP; Dorr, RT; Alberts, DS
    The state-of-the-art in chemoprevention of skin cancer
    EUROPEAN JOURNAL OF CANCER
    
    S.P. Stratton et al., "The state-of-the-art in chemoprevention of skin cancer", EUR J CANC, 36(10), 2000, pp. 1292-1297
12. Monsky, WL; Heddens, DK; Clark, GM; Von Hoff, DD; Coltman, CA; Dorr, RT; Alberts, DS
    Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop
    JOURNAL OF CLINICAL ONCOLOGY
    
    W.L. Monsky et al., "Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop", J CL ONCOL, 18(2), 2000, pp. 437-444
13. Bhardwaj, R; Hadley, ME; Dorr, RT; Dvorakova, K; Brooks, C; Blanchard, J
    Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, melanotan-I
    PHARMACEUTICAL RESEARCH
    
    R. Bhardwaj et al., "Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, melanotan-I", PHARM RES, 17(5), 2000, pp. 593-599
14. Stratton, SP; Bangert, JL; Alberts, DS; Dorr, RT
    Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice
    CANCER LETTERS
    
    S.P. Stratton et al., "Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice", CANCER LETT, 158(1), 2000, pp. 47-52
15. Dorr, RT; Dvorakova, K; Brooks, C; Lines, R; Levine, N; Schram, K; Miketova, P; Hruby, V; Alberts, DS
    Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle(4)-D-Phe(7)]-alpha-MSH in humans
    PHOTOCHEMISTRY AND PHOTOBIOLOGY
    
    R.T. Dorr et al., "Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle(4)-D-Phe(7)]-alpha-MSH in humans", PHOTOCHEM P, 72(4), 2000, pp. 526-532
16. Xing, CG; Wu, P; Skibo, EB; Dorr, RT
    Design of cancer-specific antitumor agents based on aziridlinylcyclopent[b]indoloquinones
    JOURNAL OF MEDICINAL CHEMISTRY
    
    C.G. Xing et al., "Design of cancer-specific antitumor agents based on aziridlinylcyclopent[b]indoloquinones", J MED CHEM, 43(3), 2000, pp. 457-466
17. Sami, SM; Dorr, RT; Alberts, DS; Solyom, AM; Remers, WA
    Analogues of amonafide and azonafide with novel ring systems
    JOURNAL OF MEDICINAL CHEMISTRY
    
    S.M. Sami et al., "Analogues of amonafide and azonafide with novel ring systems", J MED CHEM, 43(16), 2000, pp. 3067-3073
18. Dvorakova, K; Payne, CM; Tome, ME; Briehl, MM; McClure, T; Dorr, RT
    Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon
    BIOCHEMICAL PHARMACOLOGY
    
    K. Dvorakova et al., "Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon", BIOCH PHARM, 60(6), 2000, pp. 749-758
19. Mayr, CA; Sami, SM; Remers, WA; Dorr, RT
    Intracellular localization of 6- and 7-substituted 2-[2 '-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz [de,h]isoquinoline-1,3-diones (azonafides) is not the limiting factor for their cytotoxicity: an in vitro confocal microscopy study
    ANTI-CANCER DRUGS
    
    C.A. Mayr et al., "Intracellular localization of 6- and 7-substituted 2-[2 '-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz [de,h]isoquinoline-1,3-diones (azonafides) is not the limiting factor for their cytotoxicity: an in vitro confocal microscopy study", ANTI-CANC D, 10(2), 1999, pp. 163-170
20. Levine, N; Dorr, RT; Ertl, GA; Brooks, C; Alberts, DS
    Effects of a potent synthetic melanotropin, Nle(4)-D-Phe(7)-alpha-MSH (Melanotan-1) on tanning: a dose-ranging study
    JOURNAL OF DERMATOLOGICAL TREATMENT
    
    N. Levine et al., "Effects of a potent synthetic melanotropin, Nle(4)-D-Phe(7)-alpha-MSH (Melanotan-1) on tanning: a dose-ranging study", J DERM TR, 10(2), 1999, pp. 127-132
21. Lopez, AM; Wallace, L; Dorr, RT; Koff, M; Hersh, EM; Alberts, DS
    Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    A.M. Lopez et al., "Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia", CANC CHEMOT, 44(4), 1999, pp. 303-306
22. Dvorakova, K; Dorr, RT; Valcic, S; Timmermann, B; Alberts, DS
    Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    K. Dvorakova et al., "Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin", CANC CHEMOT, 43(4), 1999, pp. 331-335
23. Dorr, RT; Holmes, BC
    Dosing considerations with amifostine: A review of the literature and clinical experience
    SEMINARS IN ONCOLOGY
    
    R.T. Dorr e B.C. Holmes, "Dosing considerations with amifostine: A review of the literature and clinical experience", SEMIN ONCOL, 26(2), 1999, pp. 108-119
24. Iyengar, BS; Dorr, RT; Alberts, DS; Hersh, EM; Salmon, SE; Remers, WA
    Novel antitumor 2-cyanoaziridine-1-carboxamides
    JOURNAL OF MEDICINAL CHEMISTRY
    
    B.S. Iyengar et al., "Novel antitumor 2-cyanoaziridine-1-carboxamides", J MED CHEM, 42(3), 1999, pp. 510-514
25. Dorr, RT
    Managing extravasations of vesicant chemotherapy drugs
    ANTICANCER DRUG TOXICITY
    
    R.T. Dorr, "Managing extravasations of vesicant chemotherapy drugs", ANTICANCER DRUG TOXICITY, 1999, pp. 279-318
26. DORR RT
    RADIOPROTECTANTS - PHARMACOLOGY AND CLINICAL-APPLICATIONS OF AMIFOSTINE
    Seminars in radiation oncology
    
    R.T. Dorr, "RADIOPROTECTANTS - PHARMACOLOGY AND CLINICAL-APPLICATIONS OF AMIFOSTINE", Seminars in radiation oncology, 8(4), 1998, pp. 10-13
27. DORR RT; MEYERS R; SNEAD K; LIDDIL JD
    ANALYTICAL AND BIOLOGICAL INEQUIVALENCE OF 2 COMMERCIAL FORMULATIONS OF THE ANTITUMOR AGENT BLEOMYCIN
    Cancer chemotherapy and pharmacology
    
    R.T. Dorr et al., "ANALYTICAL AND BIOLOGICAL INEQUIVALENCE OF 2 COMMERCIAL FORMULATIONS OF THE ANTITUMOR AGENT BLEOMYCIN", Cancer chemotherapy and pharmacology, 42(2), 1998, pp. 149-154
28. DORR RT; BELLAMY W; LIDDIL JD; BAKER A; BAIR KW
    CORRELATION OF CYTOTOXICITY AND PROTEIN-ASSOCIATED DNA STRAND BREAKS FOR 2-(ARYLMETHYLAMINO)-1,3-PROPANEDIOLS
    Anti-cancer drug design (Print)
    
    R.T. Dorr et al., "CORRELATION OF CYTOTOXICITY AND PROTEIN-ASSOCIATED DNA STRAND BREAKS FOR 2-(ARYLMETHYLAMINO)-1,3-PROPANEDIOLS", Anti-cancer drug design (Print), 13(7), 1998, pp. 825-835
29. MAYR CA; SAMI SM; REMERS WA; DORR RT
    IDENTIFICATION AND CHARACTERIZATION OF IN-VITRO METABOLITES OF -1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONE (AZONAFIDE)
    Drug metabolism and disposition
    
    C.A. Mayr et al., "IDENTIFICATION AND CHARACTERIZATION OF IN-VITRO METABOLITES OF -1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONE (AZONAFIDE)", Drug metabolism and disposition, 26(2), 1998, pp. 105-109
30. DVORAKOVA K; DORR RT; GALLEGOS A; MCCLURE T; POWIS G
    PHARMACOKINETIC STUDIES OF THE HERBICIDE AND ANTITUMOR COMPOUND ORYZALIN IN MICE
    Journal of chromatography B. Biomedical sciences and applications
    
    K. Dvorakova et al., "PHARMACOKINETIC STUDIES OF THE HERBICIDE AND ANTITUMOR COMPOUND ORYZALIN IN MICE", Journal of chromatography B. Biomedical sciences and applications, 696(2), 1997, pp. 275-281
31. DORR RT
    CLINICAL-PHARMACOLOGY OF TAXANES AS RADIOSENSITIZERS AND THE THIOL-BASED RADIOPROTECTANT AMIFOSTINE
    Seminars in radiation oncology
    
    R.T. Dorr, "CLINICAL-PHARMACOLOGY OF TAXANES AS RADIOSENSITIZERS AND THE THIOL-BASED RADIOPROTECTANT AMIFOSTINE", Seminars in radiation oncology, 7(3), 1997, pp. 66-76
32. MAYR CA; SAMI SM; DORR RT
    IN-VITRO CYTOTOXICITY AND DNA-DAMAGE PRODUCTION IN CHINESE-HAMSTER OVARY CELLS AND TOPOISOMERASE-II INHIBITION BY 1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES WITH SUBSTITUTIONS AT THE 6-POSITION AND 7-POSITION (AZONAFIDES)
    Anti-cancer drugs
    
    C.A. Mayr et al., "IN-VITRO CYTOTOXICITY AND DNA-DAMAGE PRODUCTION IN CHINESE-HAMSTER OVARY CELLS AND TOPOISOMERASE-II INHIBITION BY 1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES WITH SUBSTITUTIONS AT THE 6-POSITION AND 7-POSITION (AZONAFIDES)", Anti-cancer drugs, 8(3), 1997, pp. 245-256
33. PAINEMURRIETA GD; TAYLOR CW; CURTIS RA; LOPEZ MHA; DORR RT; JOHNSON CS; FUNK CY; THOMPSON F; HERSH EM
    HUMAN TUMOR-MODELS IN THE SEVERE COMBINED IMMUNE-DEFICIENT (SCID) MOUSE
    Cancer chemotherapy and pharmacology
    
    G.D. Painemurrieta et al., "HUMAN TUMOR-MODELS IN THE SEVERE COMBINED IMMUNE-DEFICIENT (SCID) MOUSE", Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 209-214
34. DORR RT
    PHARMACOLOGY OF THE TAXANES
    Pharmacotherapy
    
    R.T. Dorr, "PHARMACOLOGY OF THE TAXANES", Pharmacotherapy, 17(5), 1997, pp. 96-104
35. TAYLOR CW; DALTON WS; MOSLEY K; DORR RT; SALMON SE
    COMBINATION CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, VINCRISTINE, ADRIAMYCIN, AND DEXAMETHASONE (CVAD) PLUS ORAL QUININE AND VERAPAMIL IN PATIENTS WITH ADVANCED BREAST-CANCER
    Breast cancer research and treatment
    
    C.W. Taylor et al., "COMBINATION CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, VINCRISTINE, ADRIAMYCIN, AND DEXAMETHASONE (CVAD) PLUS ORAL QUININE AND VERAPAMIL IN PATIENTS WITH ADVANCED BREAST-CANCER", Breast cancer research and treatment, 42(1), 1997, pp. 7-14
36. UGWU SO; BLANCHARD J; DORR RT; LEVINE N; BROOKS C; HADLEY ME; AICKIN M; HRUBY VJ
    SKIN PIGMENTATION AND PHARMACOKINETICS OF MELANOTAN-I IN HUMANS
    Biopharmaceutics & drug disposition
    
    S.O. Ugwu et al., "SKIN PIGMENTATION AND PHARMACOKINETICS OF MELANOTAN-I IN HUMANS", Biopharmaceutics & drug disposition, 18(3), 1997, pp. 259-269
37. IYENGAR BS; DORR RT; ALBERTS DS; SOLYOM AM; KRUTZSCH M; REMERS WA
    1,4-DISUBSTITUTED ANTHRACENE ANTITUMOR AGENTS
    Journal of medicinal chemistry
    
    B.S. Iyengar et al., "1,4-DISUBSTITUTED ANTHRACENE ANTITUMOR AGENTS", Journal of medicinal chemistry, 40(23), 1997, pp. 3734-3738
38. SAMI SM; DORR RT; ALBERTS DS; SOLYOM AM; REMERS WA
    1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES WITH SUBSTITUENTS AT POSITION-4, POSITION-8, POSITION-9, POSITION-10, AND POSITION-11 - SYNTHESIS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS (VOL 39, PG 4978, 1996)
    Journal of medicinal chemistry
    
    S.M. Sami et al., "1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES WITH SUBSTITUENTS AT POSITION-4, POSITION-8, POSITION-9, POSITION-10, AND POSITION-11 - SYNTHESIS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS (VOL 39, PG 4978, 1996)", Journal of medicinal chemistry, 40(16), 1997, pp. 2660-2660
39. DORR RT
    SKIN ULCERATION POTENTIAL OF PACLITAXEL IN A MOUSE SKIN MODEL IN-VIVO- REPLY
    Cancer
    
    R.T. Dorr, "SKIN ULCERATION POTENTIAL OF PACLITAXEL IN A MOUSE SKIN MODEL IN-VIVO- REPLY", Cancer, 79(11), 1997, pp. 2268-2269
40. TRICOT G; ALBERTS DS; JOHNSON C; ROE DJ; DORR RT; BRACY D; VESOLE DH; JAGANNATH S; MEYERS R; BARLOGIE B
    SAFETY OF AUTOTRANSPLANTS WITH HIGH-DOSE MELPHALAN IN RENAL-FAILURE -A PHARMACOKINETIC AND TOXICITY STUDY
    Clinical cancer research
    
    G. Tricot et al., "SAFETY OF AUTOTRANSPLANTS WITH HIGH-DOSE MELPHALAN IN RENAL-FAILURE -A PHARMACOKINETIC AND TOXICITY STUDY", Clinical cancer research, 2(6), 1996, pp. 947-952
41. DORR RT; LAGEL K; MCLEAN S
    CARDIOPROTECTION OF RAT-HEART MYOCYTES WITH AMIFOSTINE (ETHYOL(R)) AND ITS FREE THIOL, WR-1065, IN-VITRO
    European journal of cancer
    
    R.T. Dorr et al., "CARDIOPROTECTION OF RAT-HEART MYOCYTES WITH AMIFOSTINE (ETHYOL(R)) AND ITS FREE THIOL, WR-1065, IN-VITRO", European journal of cancer, 32A, 1996, pp. 21-25
42. PETERSEN EA; GRAYSON JB; HERSH EM; DORR RT; CHIANG SM; OKA M; PROFFITT RT
    LIPOSOMAL AMIKACIN - IMPROVED TREATMENT OF MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN THE BEIGE MOUSE MODEL
    Journal of antimicrobial chemotherapy
    
    E.A. Petersen et al., "LIPOSOMAL AMIKACIN - IMPROVED TREATMENT OF MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN THE BEIGE MOUSE MODEL", Journal of antimicrobial chemotherapy, 38(5), 1996, pp. 819-828
43. DORR RT; DVORAKOVA K; SNEAD K; ALBERTS DS; SALMON SE; PETTIT GR
    ANTITUMOR-ACTIVITY OF COMBRETASTATIN-A4 PHOSPHATE, A NATURAL PRODUCT TUBULIN INHIBITOR
    Investigational new drugs
    
    R.T. Dorr et al., "ANTITUMOR-ACTIVITY OF COMBRETASTATIN-A4 PHOSPHATE, A NATURAL PRODUCT TUBULIN INHIBITOR", Investigational new drugs, 14(2), 1996, pp. 131-137
44. ALBERTS DS; GOLDMAN R; XU MJ; DORR RT; QUINN J; WELCH K; GUILLENRODRIGUEZ J; AICKIN M; PENG YM; LOESCHER L; GENSLER H
    DISPOSITION AND METABOLISM OF TOPICALLY ADMINISTERED ALPHA-TOCOPHEROLACETATE - A COMMON INGREDIENT OF COMMERCIALLY AVAILABLE SUNSCREENS AND COSMETICS
    Nutrition and cancer
    
    D.S. Alberts et al., "DISPOSITION AND METABOLISM OF TOPICALLY ADMINISTERED ALPHA-TOCOPHEROLACETATE - A COMMON INGREDIENT OF COMMERCIALLY AVAILABLE SUNSCREENS AND COSMETICS", Nutrition and cancer, 26(2), 1996, pp. 193-201
45. DORR RT
    CYTOPROTECTIVE AGENTS FOR ANTHRACYCLINES
    Seminars in oncology
    
    R.T. Dorr, "CYTOPROTECTIVE AGENTS FOR ANTHRACYCLINES", Seminars in oncology, 23(4), 1996, pp. 23-34
46. DORR RT; LINES R; LEVINE N; BROOKS C; XIANG L; HRUBY VJ; HADLEY ME
    EVALUATION OF MELANOTAN-II, A SUPERPOTENT CYCLIC MELANOTROPIC PEPTIDEIN A PILOT PHASE-I CLINICAL-STUDY
    Life sciences
    
    R.T. Dorr et al., "EVALUATION OF MELANOTAN-II, A SUPERPOTENT CYCLIC MELANOTROPIC PEPTIDEIN A PILOT PHASE-I CLINICAL-STUDY", Life sciences, 58(20), 1996, pp. 1777-1784
47. SAMI SM; DORR RT; SOLYOM AM; ALBERTS DS; IYENGAR BS; REMERS WA
    6-SUBSTITUTED AND 7-SUBSTITUTED 1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES - SYNTHESIS, NUCLEOPHILIC DISPLACEMENTS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS
    Journal of medicinal chemistry
    
    S.M. Sami et al., "6-SUBSTITUTED AND 7-SUBSTITUTED 1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES - SYNTHESIS, NUCLEOPHILIC DISPLACEMENTS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS", Journal of medicinal chemistry, 39(8), 1996, pp. 1609-1618
48. SAMI SM; DORR RT; ALBERTS DS; SOLYOM AM; REMERS WA
    1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES WITH SUBSTITUENTS AT POSITION-4, POSITION-8, POSITION-9, POSITION-10, AND POSITION-11 - SYNTHESIS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS
    Journal of medicinal chemistry
    
    S.M. Sami et al., "1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES WITH SUBSTITUENTS AT POSITION-4, POSITION-8, POSITION-9, POSITION-10, AND POSITION-11 - SYNTHESIS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS", Journal of medicinal chemistry, 39(25), 1996, pp. 4978-4987
49. DORR RT; SNEAD K; LIDDIL JD
    SKIN ULCERATION POTENTIAL OF PACLITAXEL IN A MOUSE SKIN MODEL IN-VIVO
    Cancer
    
    R.T. Dorr et al., "SKIN ULCERATION POTENTIAL OF PACLITAXEL IN A MOUSE SKIN MODEL IN-VIVO", Cancer, 78(1), 1996, pp. 152-156
50. DORR RT; MCLEAN S; ALBERTS DS; SPEICHER L; CAPIZZI RL
    SELECTIVE CARDIOPROTECTION OF RAT-HEART MYOCYTES EXPOSED TO DNA INTERCALATING AGENTS USING AMIFOSTINE (AMI) AND ITS DEPHOSPHORYLATED METABOLITE, WR-1065
    European journal of cancer
    
    R.T. Dorr et al., "SELECTIVE CARDIOPROTECTION OF RAT-HEART MYOCYTES EXPOSED TO DNA INTERCALATING AGENTS USING AMIFOSTINE (AMI) AND ITS DEPHOSPHORYLATED METABOLITE, WR-1065", European journal of cancer, 31A, 1995, pp. 579-579
51. DORR RT; BOOL KL
    ANTIDOTE STUDIES OF VINORELBINE-INDUCED SKIN ULCERATION IN THE MOUSE
    Cancer chemotherapy and pharmacology
    
    R.T. Dorr e K.L. Bool, "ANTIDOTE STUDIES OF VINORELBINE-INDUCED SKIN ULCERATION IN THE MOUSE", Cancer chemotherapy and pharmacology, 36(4), 1995, pp. 290-292
52. KINTZEL PE; DORR RT
    ANTICANCER DRUG RENAL TOXICITY AND ELIMINATION - DOSING GUIDELINES FOR ALTERED RENAL-FUNCTION
    Cancer treatment reviews
    
    P.E. Kintzel e R.T. Dorr, "ANTICANCER DRUG RENAL TOXICITY AND ELIMINATION - DOSING GUIDELINES FOR ALTERED RENAL-FUNCTION", Cancer treatment reviews, 21(1), 1995, pp. 33-64
53. DORR RT; LIDDIL JD; KLEIN MK; HERSH EM
    PRECLINICAL PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF IMEXON
    Investigational new drugs
    
    R.T. Dorr et al., "PRECLINICAL PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF IMEXON", Investigational new drugs, 13(2), 1995, pp. 113-116
54. SAMI SM; DORR RT; SOLYOM AM; ALBERTS DS; REMERS WA
    AMINO-SUBSTITUTED 1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES - SYNTHESIS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP
    Journal of medicinal chemistry
    
    S.M. Sami et al., "AMINO-SUBSTITUTED 1,2-DIHYDRO-3H-DIBENZ[DE,H]ISOQUINOLINE-1,3-DIONES - SYNTHESIS, ANTITUMOR-ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP", Journal of medicinal chemistry, 38(6), 1995, pp. 983-993
55. KOELLER JM; BURRIS HA; DORR RT; FINLEY RS; GOLDSPIEL BR; KUHN JG; ROWINSKY EK
    PHARMACEUTICAL ISSUES OF PACLITAXEL
    The Annals of pharmacotherapy
    
    J.M. Koeller et al., "PHARMACEUTICAL ISSUES OF PACLITAXEL", The Annals of pharmacotherapy, 28(5), 1994, pp. 190000005-190000036
56. PARRISH AR; DORR RT; GANDOLFI AJ; BRENDEL K
    ADULT-RAT MYOCARDIAL SLICES - A TOOL FOR STUDIES OF COMPARATIVE CARDIOTOXICITY
    Toxicology in vitro
    
    A.R. Parrish et al., "ADULT-RAT MYOCARDIAL SLICES - A TOOL FOR STUDIES OF COMPARATIVE CARDIOTOXICITY", Toxicology in vitro, 8(6), 1994, pp. 1233-1237
57. DORR RT; LIDDIL JD; IYENGAR BS; LIST AF; REMERS WA
    BIOLOGIC ACTIVITY OF A NUCLEOTIDE CONJUGATE BETWEEN MITOMYCIN-C AND CYTARABINE MONOPHOSPHATE
    Nucleosides & nucleotides
    
    R.T. Dorr et al., "BIOLOGIC ACTIVITY OF A NUCLEOTIDE CONJUGATE BETWEEN MITOMYCIN-C AND CYTARABINE MONOPHOSPHATE", Nucleosides & nucleotides, 13(8), 1994, pp. 1655-1667
58. DORR RT; LAUPER D
    DOSING ERROR IN PROTOCOL BOOK
    Journal of clinical oncology
    
    R.T. Dorr e D. Lauper, "DOSING ERROR IN PROTOCOL BOOK", Journal of clinical oncology, 12(11), 1994, pp. 2520-2520
59. PARANKA NS; DORR RT
    EFFECT OF DOXORUBICIN ON GLUTATHIONE AND GLUTATHIONE-DEPENDENT ENZYMES IN CULTURED RAT-HEART CELLS
    Anticancer research
    
    N.S. Paranka e R.T. Dorr, "EFFECT OF DOXORUBICIN ON GLUTATHIONE AND GLUTATHIONE-DEPENDENT ENZYMES IN CULTURED RAT-HEART CELLS", Anticancer research, 14(5A), 1994, pp. 2047-2052
60. OGWU SO; BLANCHARD J; NGUYEN LD; HADLEY ME; DORR RT
    A COMPARISON OF HPLC AND BIOASSAY METHODS FOR PLASMA MELANOTAN-II (MT-II) DETERMINATION - APPLICATION TO A PHARMACOKINETIC STUDY IN RATS
    Biopharmaceutics & drug disposition
    
    S.O. Ogwu et al., "A COMPARISON OF HPLC AND BIOASSAY METHODS FOR PLASMA MELANOTAN-II (MT-II) DETERMINATION - APPLICATION TO A PHARMACOKINETIC STUDY IN RATS", Biopharmaceutics & drug disposition, 15(5), 1994, pp. 383-390
61. DORR RT; LAGEL K
    EFFECT OF SULFHYDRYL COMPOUNDS AND GLUTATHIONE DEPLETION ON RAT-HEARTMYOCYTE TOXICITY INDUCED BY 4-HYDROPEROXYCYCLOPHOSPHAMIDE AND ACROLEIN IN-VITRO
    Chemico-biological interactions
    
    R.T. Dorr e K. Lagel, "EFFECT OF SULFHYDRYL COMPOUNDS AND GLUTATHIONE DEPLETION ON RAT-HEARTMYOCYTE TOXICITY INDUCED BY 4-HYDROPEROXYCYCLOPHOSPHAMIDE AND ACROLEIN IN-VITRO", Chemico-biological interactions, 93(2), 1994, pp. 117-128
62. TRICOL G; ALBERTS DS; ROE D; DORR RT; VESOLE DH; JAGANNATH S; BARLOGIE B
    HIGH-DOSE MELPHALAN (MEL) AND RENAL-FUNCTION IN MULTIPLE-MYELOMA (MM)
    Blood
    
    G. Tricol et al., "HIGH-DOSE MELPHALAN (MEL) AND RENAL-FUNCTION IN MULTIPLE-MYELOMA (MM)", Blood, 84(10), 1994, pp. 10000180-10000180
63. JOHNSON PD; DAWSON BV; DORR RT; HADLEY ME; LEVINE N; HRUBY VJ
    COAT COLOR DARKENING IN A DOG IN RESPONSE TO A POTENT MELANOTROPIC PEPTIDE
    American journal of veterinary research
    
    P.D. Johnson et al., "COAT COLOR DARKENING IN A DOG IN RESPONSE TO A POTENT MELANOTROPIC PEPTIDE", American journal of veterinary research, 55(11), 1994, pp. 1593-1596
64. JOHNSON PD; DAWSON BV; DORR RT; HADLEY ME; LEVINE N; HRUBY VJ
    COAT COLOR DARKENING IN A DOG IN RESPONSE TO A POTENT MELANOTROPIC PEPTIDE
    American journal of veterinary research
    
    P.D. Johnson et al., "COAT COLOR DARKENING IN A DOG IN RESPONSE TO A POTENT MELANOTROPIC PEPTIDE", American journal of veterinary research, 55(11), 1994, pp. 1593-1596
65. DORR RT
    CORRECTION TO CANCER-THERAPY PROTOCOLS
    American journal of hospital pharmacy
    
    R.T. Dorr, "CORRECTION TO CANCER-THERAPY PROTOCOLS", American journal of hospital pharmacy, 51(21), 1994, pp. 2727-2727
66. MEYSKENS FL; SURWIT E; MOON TE; CHILDERS JM; DAVIS JR; DORR RT; JOHNSON CS; ALBERTS DS
    ENHANCEMENT OF REGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA-II (MODERATE DYSPLASIA) WITH TOPICALLY APPLIED ALL-TRANS-RETINOIC ACID - A RANDOMIZED TRIAL
    Journal of the National Cancer Institute
    
    F.L. Meyskens et al., "ENHANCEMENT OF REGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA-II (MODERATE DYSPLASIA) WITH TOPICALLY APPLIED ALL-TRANS-RETINOIC ACID - A RANDOMIZED TRIAL", Journal of the National Cancer Institute, 86(7), 1994, pp. 539-543